Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

被引:6
|
作者
Tariq, Raseen [1 ,2 ]
Mukhija, Dhruvika [3 ]
Gupta, Arjun [4 ]
Singh, Siddharth [5 ]
Pardi, Darrell S. [1 ]
Khanna, Sahil [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA
[2] Rochester Gen Hosp, Dept Internal Med, Rochester, NY 14621 USA
[3] Cleveland Clin, Dept Internal Med, Cleveland, OH 44106 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA
[5] Univ Calif San Diego, Div Gastroenterol & Hepatol, La Jolla, CA 92093 USA
来源
关键词
Clostridium difficile infection; incidence; meta-analysis; statins; DECREASED RISK; MORTALITY; SIMVASTATIN; OUTPATIENT; INPATIENT; COMMUNITY; SEVERITY; VETERANS; THERAPY;
D O I
10.2147/IDR.S156475
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: Statins have pleiotropic effects beyond cholesterol lowering by immune modulation. The association of statins with primary Clostridium difficile infection (CDI) is unclear as studies have reported conflicting findings. We performed a systematic review and meta-analysis to evaluate the association between statin use and CDI. Patients and methods: We searched MEDLINE, Embase, and Web of Science from January 1978 to December 2016 for studies assessing the association between statin use and CDI. The Newcastle-Ottawa Scale was used to assess the methodologic quality of included studies. Weighted summary estimates were calculated using generalized inverse variance with randomeffects model. Results: Eight studies (6 case-control and 2 cohort) were included in the meta-analysis, which comprised 156,722 patients exposed to statins and 356,185 controls, with 34,849 total cases of CDI available in 7 studies. The rate of CDI in patients with statin use was 4.3%, compared with 7.8% in patients without statin use. An overall meta-analysis of 8 studies using the random-effects model demonstrated that statins may be associated with a decreased risk of CDI (maximally adjusted odds ratio [OR], 0.80; 95% CI, 0.66-0.97; P=0.02). There was significant heterogeneity among the studies, with an I-2 of 79%. No publication bias was seen. Meta-analysis of studies that adjusted for confounders revealed no protective effect of statins (adjusted OR, 0.84; 95% CI, 0.70-1.01; P=0.06, I-2=75%). However, a meta-analysis of only full-text studies using the random-effects model demonstrated a decreased risk of CDI with the use of statins (OR 0.77; 95% CI, 0.61-0.99; P=0.04, I-2=85%). Conclusion: Meta-analyses of existing studies suggest that patients prescribed a statin may be at decreased risk for CDI. The results must be interpreted with caution given the significant heterogeneity and lack of benefit on analysis of studies that adjusted for confounders.
引用
下载
收藏
页码:405 / 416
页数:12
相关论文
共 50 条
  • [21] The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact
    Borren, Nienke Z.
    Ghadermarzi, Shadi
    Hutfless, Susan
    Ananthakrishnan, Ashwin N.
    PLOS ONE, 2017, 12 (05):
  • [22] Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: A systematic review and meta-analysis
    Babar, Sumbal
    El Kurdi, Bara
    El Iskandarani, Mahmoud
    Haddad, Ibrahim
    Imam, Zaid
    Alomari, Mohammad
    Myers, James
    Moorman, Jonathan
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2020, 41 (11): : 1302 - 1309
  • [23] Effect of passive immunotherapy against Clostridium difficile infection: a systematic review and meta-analysis
    Diraviyam, Thirumalai
    He, Jin-Xin
    Chen, Chen
    Zhao, Bin
    Michael, Antonysamy
    Zhang, Xiaoying
    IMMUNOTHERAPY, 2016, 8 (05) : 649 - 663
  • [24] Gastric Acid Suppression and Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis
    Khanna, Sahil
    Singh, Siddharth
    Pardi, Darrell
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S571 - S572
  • [25] Regional differences in temporal incidence of Clostridium difficile infection: a systematic review and meta-analysis
    Ho, Jeffery
    Wong, Sunny H.
    Doddangoudar, Vijaya C.
    Boost, Maureen, V
    Tse, Gary
    Ip, Margaret
    AMERICAN JOURNAL OF INFECTION CONTROL, 2020, 48 (01) : 89 - 94
  • [26] Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis
    Beinortas, Tumas
    Burr, Nicholas E.
    Wilcox, Mark H.
    Subramanian, Venkataraman
    LANCET INFECTIOUS DISEASES, 2018, 18 (09): : 1035 - 1044
  • [27] Proton pump inhibitors and associated risk of Clostridium difficile infection: a systematic review and meta-analysis of observational studies
    Kwok, C. S.
    Arthur, A. K.
    Anibueze, C. I.
    Cavallazzi, R.
    Singh, S.
    Loke, Y. K.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (06) : 985 - 985
  • [28] Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: A Systematic Review and Meta-analysis
    Furuya-Kanamori, Luis
    Stone, Jennifer C.
    Clark, Justin
    McKenzie, Samantha J.
    Yakob, Laith
    Paterson, David L.
    Riley, Thomas V.
    Doi, Suhail A. R.
    Clements, Archie C.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2015, 36 (02): : 132 - 141
  • [29] RISK FACTORS AND OUTCOMES ASSOCIATED WITH CLOSTRIDIUM DIFFICILE INFECTION IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Balram, Bhairavi
    Al Khoury, Alex
    Lakatos, Peter L.
    Bessissow, Talat
    GASTROENTEROLOGY, 2018, 154 (06) : S68 - S68
  • [30] The Association between Histamine 2 Receptor Antagonist Use and Clostridium difficile Infection: A Systematic Review and Meta-analysis
    Tleyjeh, Imad M.
    Bin Abdulhak, Aref A.
    Riaz, Muhammad
    Garbati, Musa A.
    Al-Tannir, Mohamad
    Alasmari, Faisal A.
    AlGhamdi, Mushabab
    Khan, Abdur Rahman
    Erwin, Patricia J.
    Sutton, Alex J.
    Baddour, Larry M.
    PLOS ONE, 2013, 8 (03):